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Abstract 
 
Glioblastoma (GBM) is the most common and deadly primary brain tumor, 
accounting for over 10,000 new cancer diagnoses in the United States each 
year. The poor prognosis for GBM patients necessitates novel biological 
treatments. One such approach is the use of oncolytic herpes simplex virus 1 
(oHSV). Like many novel treatments oHSV therapy causes off target effects that 
are not yet well understood. Our lab has demonstrated that oHSV treatment 
increases the vascularity of brain tumors. The goal of this study is to determine 
the mechanism by which oHSV treatment increases the vascularity of brain 
tumors. Preliminary data suggested the hypoxia inducible factor-1 alpha (HIF1α) 
may be activated in cells infected with oHSV, even in normal oxygen conditions. 
HIF1α is a transcription factor, which activates a variety of genes in response to a 
lack of oxygen. We hypothesized that HIF1α activation may be responsible for 
the increased vascularity of oHSV treated brain tumors. A screen of 
targetscan.org for the predicted target genes of herpes simplex virus 1 (HSV-1) 
revealed multiple miRNAs predicted to target a protein called, factor inhibiting 
HIF1α (FIH). This protein functionally inhibits HIF1α activation by preventing the 
binding of HIF1α to DNA. We believed that FIH would be negatively regulated in 
GBM cells infected with oHSV, thus allowing HIF1α activation. In this study, we 
demonstrate that HSV-1 expresses two miRNA molecules, which target and 
down regulate FIH. Transfection of miRNA inhibitors (antagomirs) was able to 
successfully abrogate the virus' ability to down regulate FIH as demonstrated by 
quantitative PCR and western blot. Moreover, transfection of HSV-1 miRNA 
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mimics in the absence of virus was able to down regulate FIH protein levels 
(western blot) and activate the expression of a variety of HIF1α driven genes, 
including VEGF and IL-8 (quantitative PCR). However, after analyzing HIF1α 
promoter activity in a variety of cell lines, we determined that HIF1α was not 
activated during oHSV infection. The expression of VEGF and IL-8 was likely due 
to the activation of another transcription factor.  
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Introduction  
Background 
Glioblastoma (GBM) is the most common and deadly primary brain tumor, 
accounting for about 10,000 new cancer diagnoses in the United States each 
year.1 Although GBM is relatively rare compared to other cancers, these tumors 
are responsible for a disproportionately high amount of cancer deaths, and the 
majority of GBM patients will succumb to their disease within 12-15 months.2 
GBM tumors are especially difficult to treat due to their invasive nature and 
resistance to standard chemotherapies. The poor prognosis for GBM patients 
necessitates novel biological treatments. One such approach is the use of 
oncolytic herpes simplex virus 1 (oHSV).3 These genetically altered herpes 
simplex 1 viruses (HSV-1) potently kill cancer cells but are unable to infect 
normal cells.4 oHSV therapy offers a potentially revolutionary approach for 
treating highly refractory cancers such as GBM. Additionally, there are five 
clinical trials investigating the use of oHSV as a cancer therapy that are either 
actively recruiting or completed. (NCT02031965, NCT00028158, NCT01721018, 
NCT00931931, NCT01017185) 
Our lab has demonstrated that oHSV treatment increases the vascularity 
in mouse models of glioma tumors following oHSV treatment.5 These new blood 
vessels are able to sustain tumor growth and clear out infectious oHSV. We have 
also determined that the hypoxia inducible factor-1 alpha (HIF1α) is activated in 
cells infected with oHSV. HIF1α is a transcription factor that activates a variety of 
genes in response to a lack of oxygen.6 Interestingly, we found that HIF1α 
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transcriptional activity is activated in oHSV infected cell lines even under normal 
oxygen conditions. A fundamental consequence of HIF1α activation is the 
formation of new blood vessels.7 We believe that HIF1α activation may be 
responsible for the increased vascularity of oHSV treated brain tumors. 
 To investigate the mechanism of HIF1α activation, I explored all microRNA 
(miRNA) molecules expressed by HSV-1. Because our oncolytic virus is derived 
from HSV-1, it expresses the same miRNA profile as this virus. Using a miRNA 
target prediction program (targetscan.org), I screened all 26 miRNA sequences 
expressed by HSV-1 for potential target genes. Interestingly, I found that HSV-1 
encodes for two different miRNAs, HSV-miRNA-6 and HSV-miRNA-16, each 
predicted to target the protein, factor inhibiting HIF1α (FIH). This protein 
functionally inhibits HIF1α activation by preventing the binding of HIF1α to the 
CBP/p300 coactivating complex, a protein complex necessary for HIF1α to bind 
to DNA.8 Under normal oxygen conditions, FIH works in conjunction with a family 
of proteins, the prolyl hydroxylase domain (PHD) proteins to regulate HIF1α. The 
PHDs and FIH both add hydroxyl groups to HIF1α to target the protein for 
degradation and prevent DNA binding and (Fig. 1).9 
 Notably, it has previously been demonstrated that FIH is down regulated 
by human miRNA-31 in head & neck carcinoma, and that this activates the HIF1α 
mediated hypoxia response in these tumors.10 It is possible that HSV-1 has 
evolved a method to mimic this human miRNA regulation to activate HIF1α, 
which could create a cellular environment that promotes viral replication. For the 
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remainder of this proposal, when I discuss HSV-1 miRNA, I am referring to the 
two miRNA molecules expressed by HSV-1 that were predicted to target FIH. 
 
 
 
 
 
Significance 
By determining the cause of HIF1α activation we will expand the current 
understanding of viral regulation of the host genome. Although there are 
examples of HSV-1 encoded miRNAs that regulate viral gene expression, to our 
knowledge no lab has demonstrated that any of these miRNAs are utilized to 
regulate host gene expression. Discovering that HSV-1 expresses miRNAs in 
order to regulate a host transcription factor would be a novel and significant 
discovery. Additionally, this discovery will lay down the rationale to create a next 
generation oHSV that lacks the ability to control the host hypoxia response and 
does not produce the negative effect of increased angiogenesis. Eventually, we 
will potentially develop a virus with mutations in the regions encoding for the 
miRNA molecules that target FIH. If these mutations do not compromise the 
Mechanism of HIF1α activity. 
Under normal oxygen conditions, FIH and 
PHD hydroxylate HIF1α. While 
hydroxylation by PHD targets HIF1α for 
proteasomal degradation, hydroxylation by 
FIH prevents binding of HIF1α to 
CBP/p300 coactivation complex. Without 
binding to this coactivator, HIF1α cannot 
bind to its DNA promoter region. Under 
moderate hypoxia, FIH activity continues 
to prevent HIF1α activity. Upon severe 
hypoxia (1% O2), FIH activity and PHD 
are both deactivated, allowing HIF1α to 
bind to DNA and activate a variety of 
genes.9 
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replication of the virus, this virus could be an improvement on current oHSV 
therapy. 
 
Objectives 
 I hypothesize that herpes simplex virus 1 encodes for miRNAs that target 
FIH mRNA to down-regulate its translation, thus stimulating HIF1α activation. FIH 
is known to be regulated by human miRNA-31, it is possible that HSV-1 has 
evolved a similar mechanism to target FIH and activate HIF1α.10 Additionally, we 
have already established that HIF1α is activated in oHSV-infected cells in 
normoxia, and we have found two HSV-1 miRNAs predicted to target FIH 
(prediction by targetscan.org).  
Specific Aim 1: Demonstrate that HSV-1 encoded miRNAs are capable of 
targeting FIH mRNA to down regulate FIH protein levels. 
Specific Aim 2: Demonstrate that expression of the HSV-1 encoded miRNA is 
necessary to induce the HIF1α mediated hypoxia response.  
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Materials and Methods 
Cells and Viruses 
 LN229 and UT51T3 glioma cells have been cultured in our lab and are 
maintained in Dulbecco’s Modiefied Eagle Media (DMEM) supplemented with 
10% fetal bovine serum, 100ug/mL penicillin, and 100ug/mL of streptomycin. To 
passage cells, monolayers are treated with trypsin-EDTA to dissociate cells, and 
one tenth of the cells are transferred to another plate. 
 Viruses 34.5ENVE and rHSVQ were developed previously.11 rHSVQ has 
green fluorescent protein inserted within the ICP6 locus (viral rubonucleotide 
reductase), which both imparts its oncolytic characteristic and also allows the 
viral replication to be tracked under a fluorescent microscope.12 Additionally both 
copies of viral ICP34.5 have been deleted. In the virus, 34.5ENVE, the ICP34.5 
gene, which dampens the cells innate immune response, has been reinserted 
under the Nestin promoter, which is active in glioma cells. Additionally, 
VSTAT120 has been inserted under a Nestin promoter as well. This protein is the 
extracellular fragment of brain angiogenesis inhibitor-1 (BAI1), which gives this 
virus its anti-angiogenic properties.13 
 
Western Blots 
SDS-PAGE was used to solubilize cell lysates, which were transferred to 
polyvinylidene difluoride (PVDF) membranes. These membranes were blocked 
and then incubated with antibodies targeting FIH and GAPDH (Cell Signaling 
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Technology, Waltham, MA). The immunoreactive bands were visualized using a 
using enhanced chemiluminescence (ECL) (GE Healthcare, Piscataway, NJ). 
 
Quantitative Polymerase Chain Reaction 
 Total RNA was purified from cellular lysates using RNeasy mini kit 
(Qiagen). This RNA was then converted to cDNA using the Superscript First 
Strand Synthesis Kit (Invitrogen). cDNA was expanded using custom primers for 
FIH, VEGF, IL-8. And GAPDH and the double stranded DNA product was 
quantified using Sybr Green Master Mix (Life-Technologies). Rather than using 
custom primers and Sybr Green, HSV miRNA-H6 and miRNA-H16 were 
quantified using taqman qPCR primers. 
 
Viral Quantification Assay 
 Infectious viral particles were quantified by viral plaque assay. Cells were 
infected with oHSV and 72 hours after infection whole cell lysates were collected. 
We released oHSV from cells by three freeze-thaw cycles, and we purified oHSV 
by centrifuging cell lysate-virus mixtures at 4000 xG for 20 minutes and collecting 
the supernatant. The supernatant was diluted to concentrations of 1/30th, 1/90th, 
1/270th, 1/810th, 1/2430th, and 1/7290th by serial dilution. Diluted virus was added 
to 10,000 cells of Vero African Green Monkey Kidney Cells in 96 well plates, and 
after 14 hours human IgG was added to neutralize infectious particles in the 
supernatant. 72 hours following infection, viral particles were quantified by 
counting the viral plaques present on the vero cells.  
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Luciferase Assays 
 Cell lysates were collected with Passive Lysis Buffer (Promega), cell 
debris were collected by centrifugation, and the supernatant containing luciferase 
protein was frozen. Luciferase levels were quantified using Luciferase Assay 
System (Promega). 20 uL of samples were prepared and 200 uL of luciferase 
substrate was added to each well. The luminescence of the luciferase was 
measured using Fluorstar Optima plate reader. Luminescence levels were 
normalized to protein levels that were measured using the Reducing Agent 
Compatible BCA Protein Assay Kit (Pierce). 
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Results 
 
Down Regulation of FIH following HSV-1 Infection 
 To initially investigate the relation of oHSV to the host hypoxia response, 
we measured at the expression of Factor Inhibiting HIF1α (FIH) following viral 
infection. When cells were infected with increasing doses of two oncolytic herpes 
viruses, 34.5ENVE and rHSVQ, the FIH protein level within a cell decreased in a 
dose dependent manner. Although FIH protein levels were decreasing, HIF1α 
levels were unaffected (Fig. 1A).  
 We next sought to investigate if this effect was specific to HSV-1 or a 
more general cellular response to viral infection. We infected cells with a panel of 
wild-type viruses: HSV, Adenovirus (Ad), Vesicular Stomatitis Virus (VSV), and 
Newcastle Disease Virus (NDV). In the cells infected with wild-type HSV-1, FIH 
protein was almost undetectable in the cells. In contrast FIH was up regulated in 
cells infected with the other types of virus. This suggested that HSV-1, as well as 
our oHSV vectors, have potentially developed a method to specifically target 
human FIH for down regulation.  
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Figure 1 
 
Figure 1: Down Regulation of FIH following HSV-1 infection. (A) 
U251T3 glioma cells were infected with a increasing multiplicities of 
infection (MOI) of either 34.5ENVE or rHSVQ. In both cases oHSV 
decreased FIH protein levels in a dose dependent manner. (B) Vero Cells 
were infected with four different virus strains: wild type HSV-1, 
Adenovirus, Vesicular Stomatitis Virus, or Newcastle Disease Virus. FIH 
was down regulated following only HSV-1 infection.  
 
 
Down regulation of FIH is mediated by miRNA expressed by oHSV 
 We utilized the software, targetscan.org, to investigate the potential target 
genes of all miRNAs expressed by HSV-1. Because our oHSV vectors are 
derived from HSV-1, they would also express these miRNA molecules. We 
discovered 2 miRNAs, HSV miRNA-6 and HSV miRNA-16, that were predicted to 
bind to the 3’UTR of human FIH. We hypothesized that our oHSV vectors may be 
expressing enough of these two miRNAs to down regulate human FIH, thus 
activating the HIF1α hypoxia response. 
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 We were able to confirm that these miRNA molecules were expressed by 
HSV-1 by using TaqMan Quantitative PCR (QPCR) on infected cells. Indeed 
both wild-type HSV and the oHSV, 34.5ENVE, both expressed high levels of both 
miRNA, as compared to two human miRNA controls (Fig. 2A). Consistent with 
our hypothesis, when we transfected miRNA mimics of HSV miRNA-6 and HSV 
miRNA-16, FIH levels were strongly down regulated as compared to the non-
targeting control  (Fig. 2B – FIH top row, GAPDH bottom row). These results 
supported our hypothesis that our oHSV vector expresses miRNA capable of 
specifically targeting and down-regulating FIH. 
 We were curious to investigate if viral miRNA transfection had a 
measurable effect on FIH mRNA levels. We utilized QPCR to quantify FIH mRNA 
levels relative to GAPDH mRNA.  Although the miRNA had a strong effect on FIH 
protein levels, FIH mRNA was unaffected (Fig. 2C) 
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Figure 2 
 
 
Figure 2: Down regulation of FIH is mediated by miRNA expressed 
by oHSV. (A) Vero cells were infected with increasing MOI of either wild 
type HSV-1 or 34.5ENVE.  In both cases HSV miRNA-H6 and HSV 
miRNA-H16 were strongly induced. (B) U251T3 cells were transfected 
with non-targeting control RNA (NC), HSV miRNA-H6, HSV miRNA-H16, 
or CoCl2 (positive control for HIF1α activation). FIH protein (top row) 
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decreased following HSV miRNA transfection relative to GAPDH protein 
(bottom row). (C) Infecting U251T3 cells with wild type HSV-1 or 
34.5ENVE did not affect FIH mRNA levels.  
 
 
FIH down-regulation is primarily dependent upon HSV miRNA-H16 
 From this point forward my work focused on the effect of HSV miRNA-
H16. I sought to determine if viral miRNA was the primary mechanism of FIH 
down-regulation inside cells infected with oHSV. Although transfection with HSV 
miRNA-H16 was capable of down regulating FIH, transfection of miRNA mimics 
does not perfectly replicate the situation within oHSV infection. To confirm that 
miRNA was the primary cause of FIH down regulation, we pretreated cells with 
antagomirs prior to oHSV infection. Antagomirs selectively block the activity of 
miRNA molecules with specific sequences.  
 As expected, levels of FIH were reduced in infected cells treated with 
either lipofectamine (lipo) or non-targeting RNA (NC). However cells pretreated 
with an antagomir specific to HSV miRNA-H16 displayed higher levels of FIH 
apparent by western blot (Fig. 3). This data suggests that FIH is specifically 
targeted by viral miRNA and that HSV miRNA-H16 is the primary mechanism by 
which oHSV targets FIH.  
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Figure 3: FIH down-regulation is primarily dependent upon HSV 
miRNA-H16. Prior to viral treatment, U251T3 cells were transfected with 
non-targeting RNA (NC), antagomir for HSV miRNA-H16 (amiH16), or 
simply treated with lipofectamine transfection reagent (lipo) These cells 
were either left uninfected or transfected with 0.1 MOI of oHSV.  
 
 
Inhibition of HSV miRNA-H16 decreases viral replication 
  We were curious to determine if HSV miRNA-H16 was important to the 
viral replication cycle of oHSV. We continued to use antagomirs to investigate the 
importance of this miRNA. LN229 glioma cells were transfected with an 
antagomir specific to miRNA-H16 or non-targeting control RNA (NC). On the next 
day these cells were infected with GFP expressing oHSV.  The GFP allowed us 
to visualize viral infection.  
In these cells, inhibiting HSV miRNA-H16 dramatically reduced the 
replication of 34.5ENVE. When we visualized the GFP expressed in cells 
infected with virus, the cells pretreated with antagomir displayed much lower 
GFP fluorescence (Fig. 4A). Consistent with this observation were decreased 
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viral particles quantified by viral plaque assay. Our oHSV virus replicated to a 
significantly lower extent in cells pretreated with antagomir for HSV miRNA-H16 
(Fig. 4B)  
 
 
Figure 4: Inhibition of HSV miRNA-H16 decreases viral 
replication. LN229 glioma cells were pretreated with either non-
targeting RNA (HSV-amirNC), or an antagomir for HSV miRNA-H16 
(HSV-amirH16). These cells were then infected with 0.01 MOI of 
34.5ENVE. (A) 72 hours after infection we visualized GFP 
expressed by the oHSV, which revealed that HSV-
amirH16treatment decreased viral GFP transduction. (B) We used 
viral plaque assay to confirm that HSV-amirH16 transfection 
significantly decreased viral replication.  
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HSV miRNA-H16 increases the expression of HIF1α target genes 
 To investigate the effect of viral miRNA on the expression of HIF1α target 
genes, we utilized QPCR to measure the mRNA of VEGF and IL-8. We had 
hypothesized that the down-regulation of FIH may allow for increased activation 
of the HIF1α transcription factor. VEGF and IL-8 are two genes that are positively 
regulated by HIF1α activation.14 
 Consistent with our hypothesis, VEGF expression was up regulated about 
10-fold fold compared to cells treated with non-targeting miRNA (NC – Fig. 5a). 
Additionally, mRNA levels of the cytokine IL-8 was increased about 25-fold 
following transfection with HSV miRNA-H16 mimics.  
 
Figure 5: HSV miRNA-H16 increases the expression of two HIF1α 
target genes. Cells were transfected with non-targeting RNA (NC) or 
mimic for HSV miRNA-H16 (miH16). (A-B) We then performed PCR on 
VEGF and IL-8. This revealed that HSV miRNA-H16 increased 
expression of both HIF1α target genes.  
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HIF1α is not activated following oHSV infection 
The final aim of this project was to find out if oHSV activation indeed 
activated the host hypoxia response mediated by HIF1α. To investigate the 
potential HIF1α activation we created two luciferase vectors driven by the 
minimal CMV promoter (mCMV). The DNA sequence for the hypoxia response 
element (HRE) was inserted to the control luciferase vector to measure HIF1α 
transcriptional activity. 
Cells were transfected with either the control luciferase vector or the HRE-
luciferase vector, and then cells were infected with increasing MOI of oHSV or 
left uninfected. In LN229 cells infected with 0.01 MOI of oHSV, HRE activity was 
slightly elevated relative to uninfected cells (Fig. 6 A-B). This effect was not 
replicated in U251T3 cells (Fig. 6 C-D). Due to the higher basal luciferase activity 
in the HRE vector, the trend was difficult to measure in both cell lines. 
Additionally, oHSV infection increased luciferase expression in the control vector. 
These complications made us uncertain that oHSV actually induces HIF1α 
activity. Additionally even when oHSV increased HRE expression relative to the 
amount that it increased luciferase in the control vector, the induction was very 
slight. This data makes us believe that oHSV does not regulate HIF1α activation 
and that HSV miRNA-H16 likely induces an inflammatory phenotype through 
another pathway. 
 
 
 
 24 
 
Figure 6: HIF1α is not activated following oHSV infection. (A-B) 
LN229 cells were transfected with either an HRE luciferase reporter 
vector or a control luciferase vector. Cells were then infected with 0.01 
MOI or 0.1 MOI of 34.5ENVE and compared to uninfected cells. The HRE 
luciferase vector expressed higher basal levels of luciferase, but was 
induced to even higher expression levels following treatment with 0.01 
MOI of oHSV (A). When luciferase levels of each vector were normalized 
to their untreated control we found that 0.01 MOI of oHSV induced 
luciferase expression by a significant but small amount (B). (C-D) We 
then repeated this test in U251T3 cells but saw no effect.  
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Conclusions and Discussion 
 We sought to investigate the interplay between miRNA expressed by 
oHSV and genes involved with host hypoxia response. The novel discovery of 
this project is that HSV-1 expresses miRNA capable of directly targeting and 
inhibiting the expression of FIH. Importantly, the down-regulation of FIH was 
primarily dependent upon viral miRNA as opposed to another mechanism of 
protein degradation. To our knowledge, this is the first study to demonstrate that 
HSV-1 expresses a miRNA that is utilized to specifically down-regulate a host 
gene. Interestingly, HSV miRNA-H16 decreased FIH protein levels without 
affecting FIH mRNA levels. This is consistent with a mechanism of translational 
repression due to miRNA.15  
 It was interesting to find that expression of miRNA-H16 was vital to HSV 
replication within LN229 cells. When cells were pretreated with miRNA-H16 
antagomir prior to infection, the virus displayed much lower expression. This 
suggests that down-regulation of FIH is important for the viral replication cycle to 
be completed efficiently. It is important to note that this experiment does not 
necessarily suggest that down regulation of FIH is the reason that viral replication 
was inhibited. It is possible that HSV miRNA-H16 targets multiple genes 
simultaneously, which means that this miRNA could be important to viral miRNA 
for multiple reasons. 
 After this conclusion we finally sought to see if oHSV caused activation of 
the host hypoxia response. Although we found increased expression of HIF1α 
target genes VEGF and IL-8 following miRNA-H16 transfection, we did not 
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observe consistent HIF1α activation following oHSV infection. At this point we 
conclude that oHSV is not likely to activate the hypoxia response. The 
consistency of these results was likely affected by the use of the mCMV 
promoter. It is possible that the oHSV replication cycle increased luciferase 
activity in the control vector. In the future we will try to find a promoter compatible 
with this luciferase vector that is unaffected by viral infection. We checked 
promoter activity with a few other promoters (HSV-TK, HSP68, and SV40), but 
unfortunately all of these promoters were activated by oHSV infection as well 
(data not shown). 
 It is interesting to speculate how oHSV has developed a mechanism to 
down-regulate FIH. It is possible that HSV-1 picked up its miRNA sequences 
from related miRNA genes in the human genome. It would also be interesting to 
understand the evolutionary pressure on HSV-1 to down-regulate FIH. It is 
possible that HIF1α target genes such as VEGF are beneficial to viral infection. 
FIH may also associate with other proteins within the cell that interact with HSV-
1, which would explain the lack of consistency with the HIF1α activation assay. 
 Moving forward we plan to investigate the effect of HIF1α on viral 
replication. We can develop cells that stably express HIF1α shRNA and see if 
these cells display lower oHSV replication. Additionally we plan to further 
elucidate the importance of FIH down-regulation on viral replication. Finally, we 
plan to investigate the relevance of miRNA-H16 in vivo. It would be important to 
see how the role of this miRNA changes inside oHSV infection within a brain 
tumor.  
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